Eli Lilly is set to acquire Merida Biosciences in a deal valued at up to $2.875 billion, with payment described as in cash. The transaction is reported to involve a total consideration that can rise to that maximum figure, rather than a single fixed amount.
The two outlets report the same headline terms of the acquisition, including the target company and the upper bound of the deal value. However, the provided excerpts do not include additional deal specifics such as the exact base price, potential milestone or contingent payments, the expected timing for closing, or any regulatory and shareholder-approval conditions.
Neither source excerpted here offers context on Merida’s pipeline, Lilly’s strategic rationale for the purchase, or whether the deal is expected to broaden Lilly’s therapeutic areas. As a result, the emphasis across these reports is on the transaction size and the nature of payment, with limited information in the supplied text about broader implications.
